Breast cancer vaccines for treatment and prevention Mary L. DisisDenise L. Cecil Review 30 November 2021 Pages: 481 - 489
An overview of genetic services delivery for hereditary breast cancer Sonya ReidLucy B. SpallutoTuya Pal Review 26 January 2022 Pages: 491 - 500
Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing Phuong DinhJ. Dinny GrahamNirmala Pathmanathan Preclinical study 01 December 2021 Pages: 501 - 511
A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA Christopher G. VerdoneJennifer A. BayronRichard J. Bleicher Preclinical study 11 January 2022 Pages: 513 - 522
Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R Yapeng LiXueying ZhengGuoyou Qin Clinical trial 26 November 2021 Pages: 523 - 533
Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer Faye CoeVivek MisraMaria Ekholm Clinical trial Open access 29 November 2021 Pages: 535 - 543
Factors related to patient-reported cosmetic outcome after breast-conserving therapy for breast cancer A. T. P. M. Brands-AppeldoornR. C. M. ThommaR. M. H. Roumen Clinical trial 29 November 2021 Pages: 545 - 552
The impact of the COVID-19 pandemic on perceived access to health care and preferences for health care provision in individuals (being) treated for breast cancer Dieuwke R. Mink van der MolenClaudia A. Bargonon behalf of UMBRELLA study group Clinical trial 01 December 2021 Pages: 553 - 564
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial Nicholas TurnerRebecca A. DentMafalda Oliveira Clinical trial Open access 03 December 2021 Pages: 565 - 576
Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort M. BringuierM. CartonC. Baldini Clinical trial 05 January 2022 Pages: 577 - 587
Does conventional specimen radiography after neoadjuvant chemotherapy of breast cancer help to reduce the rate of second surgeries? Benedikt SchaefgenAnnika FunkMichael Golatta Clinical trial Open access 08 December 2021 Pages: 589 - 598
A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes Tae-Kyung YooJun KangByung Joo Chae Clinical trial 12 January 2022 Pages: 599 - 610
Circulating lipids and breast cancer prognosis in the Malmö diet and cancer study Sixten HarborgThomas P. AhernSigne Borgquist Epidemiology Open access 25 November 2021 Pages: 611 - 621
A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer Nickolas DreherMadeline MatthysLaura J. van’t Veer Epidemiology 29 November 2021 Pages: 623 - 629
Impact of rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis on psychosocial functioning Kelly A. MetcalfeAndrea EisenSteven A. Narod Epidemiology 30 November 2021 Pages: 631 - 641
Studying the association between breast cancer and renal cell carcinoma Khalid JaziehFiras BaidounJame Abraham Epidemiology 02 December 2021 Pages: 643 - 652
Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities Jazib GoharWhitney L. DoLauren E. McCullough Epidemiology 03 January 2022 Pages: 653 - 663
Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system Annie TangElad Neemanon behalf of The Permanente Medical Group Breast Research Collaborative Epidemiology 06 January 2022 Pages: 665 - 675
Yield of flow cytometry in addition to cytology for lymph node sampling in patients with incidental axillary adenopathy without a concurrent diagnosis of primary breast malignancy Roberto Lo GulloChristophe Cloutier LambertDonna D’Alessio Epidemiology 11 January 2022 Pages: 677 - 683
Safety of systemic hormone replacement therapy in breast cancer survivors Avrum Z. Bluming Letter to the Editor 07 January 2022 Pages: 685 - 686